Comparative studies of radiolabeled choline positron emission tomography, histology of primary tumor and other imaging modalities in prostate cancer: A systematic review and meta-analysis

Clinical and Translational Imaging

Volumn 1, Issue 2, 2013, Pages 99-109

  Evangelista, Laura ^a   Cervino, Anna Rita ^a   Burei, Marta ^a   Gregianin, Michele ^a   Saladini, Giorgio ^a   Marzola, Maria Cristina ^b   Chondrogianis, Sotirios ^b   Rubello, Domenico ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Hospital of Rovigo   (Italy)

Author keywords

Comparative studies; Meta analysis; MRI; Prostate cancer; Radiolabeled choline PET

Indexed keywords

CHOLINE C 11; FLUORINE 18 CHOLINE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER STAGING; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; META ANALYSIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 84892827345     PISSN: 22815872     EISSN: 22817565     Source Type: Journal    
DOI: 10.1007/s40336-013-0016-0     Document Type: Review

References (50)

1. Williams SG, Millar JL, Dally MJ, Sia S, Miles W, Duchesne GM (2004) What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys 58: 11-18.
2. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60.
3. Platt JF, Bree RL, Schwab RE (1987) The accuracy of CT in the staging of carcinoma of the prostate. AJR Am J Roentgenol 149: 315-318.
4. Engeler CE, Wasseman NF, Zhang G (1992) Preoperative assessment of prostatic carcinoma by computerized tomography. Weaknesses and new perspectives. Urology 40: 346-350.
5. Heidenreich AH, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N et al. (2010) Guidelines on prostate cancer. Eur Urol. available from the web-site: http://www. uroweb. org/gls/pdf/Prostate%20Cancer%202010. pdf.
6. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J et al (2000) Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164: 400-404.
7. Coakley FV, Kurhanewicz J, Lu Y, Jones KD, Swanson MG, Chang SD et al (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223: 91-97.
8. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ (1997) Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 202: 697-702.
9. Thornbury JR, Ornestein D, Choyke PL, Langlotz CP, Weinreb JC (2001) Prostate cancer: what is the future role for imaging? AJR Am J Roentgenol 176: 17-21.
10. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57: 108-111.
11. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrun A (1998) Positron emission tomography in urological oncology. J Urol 159: 347-356.
12. Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155: 994-998.
13. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18] fluoro-d-glucose. Radiology 199: 751-756.
14. Schöder H, Larson S (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34: 274-292.
15. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T et al (2006) [(18)F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33: 1387-1398.
16. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN (2006) Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 47: 262-269.
17. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D et al (2006) Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47: 1249-1254.
18. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M et al (2004) Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med 45: 1233-1236.
19. Berlin JA (1997) Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet 350: 185-186.
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3: 25.
21. Higgins JP, Thompson S, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
22. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Mata-Disc: a software for meta-analysis of test accuracy data. BMC Med Res Methodolol 6: 31.
23. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G et al (2005) Detection and localization of prostate cancer: correlation of 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 46: 1642-1649.
24. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E et al (2006) 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J of Urol 176: 954-960.
25. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Corazzini C et al (2008) [(11C)]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 35: 1065-1073.
26. Scher B, Seitz M, Albinger W, Tiling W, Tiling R, Scherr M et al (2007) Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34: 45-53.
27. Yamaguchi T, Lee J, Uemura H, Sasaki T, Takahashi N, Oka T et al (2005) Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spetroscopy. Eur J Nucl Med Mol Imaging 32: 742-748.
28. Watanabe H, Kanematsu M, Kondo H, Kako N, Yamamoto N, Yamada T et al (2010) Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging. J Magn Reson Imaging 31: 1151-1156.
29. Testa C, Schiavina R, Lodi R, Salizzoni E, Corti B, Farsad M et al (2007) Prostate cancer: sextant localization with MRI imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 244: 797-806.
30. van den Bergh L, Koole M, Isebaert S, Joniau S, Deroose CM, Oyen R et al (2012) Is there an additional value of 11C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? Inter J Rad Oncol Biol Phys 83: 1486-1492.
31. Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C et al (2012) Prostate cancer: 1HMRS-DCEMR at 3 T versus (18F)choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatcetomy (RRP). Eur J Radiol 81: 700-708.
32. Rinnab L, Blumstein NM, Mottaghy FM, Hautmann RE, Kufer R, Hohl K, Reske SN (2007) 11C-choline positron emission tomography/computed tomography and transurectal ultrasonography for staging localized prostate cancer. BJU Int 99: 1421-1426.
33. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C et al (2011) Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. QJNMMI 55: 448-457.
34. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W et al (2008) Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35: 1766-1774.
35. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M et al (2003) Value of (11C) choline positron emission tomography for re-staging prostate cancer: a comparison with (18F)fluorodeoxyglucose-positron emission tomography. J Urol 169: 1337-1340.
36. Beauregard JM, Williams SG, DeGrado TR, Roselt P, Hicks RJ (2010) Pilot comparison of 18F-fluorocholine and 18F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. JMIRO 54: 325-332.
37. Richter JA, Rodriguez M, Rioja J, Panuelas I, Marti-Climent J, Garrastachu P et al (2010) Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 12: 210-217.
38. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176.
39. Krämer S, Görich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N et al (1997) Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 70: 995-999.
40. Bott SR (2004) Prostate cancer: management of recurrent disease after radical prostatectomy. Prostatic Dis 7: 211-216.
41. Luboldt W, Kufer R, Blumstein N, Toussaint TL, Kluge A, Seeman MD, Luboldt H (2008) Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 249: 1017-1025.
42. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V et al (2010) Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 24: 485-492.
43. Picchio M, Spinapolice EG, Fallanca F, Crivellaro C, Giovacchini G, Gianolli L, Messa C (2012) (11C) choline PET/CT detection in bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J of Nucl Med Mol Imaging 39: 13-26.
44. Beheshti M, Langsteger W (2011) Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 39: 910-911.
45. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J et al (2009) The use of F-18 Choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 12: 98-107.
46. McCarthy M, Siew T, Campbell A, Lenzo N, Spry N, Vivian J, Morandeau L (2011) 18F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 38: 14-22.
47. Evangelista L, Gutilla A, Zattoni F, Muzzio PC, Zattoni F (2012) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur J Urol. doi: 10. 1016/j. eururo. 2012. 09. 039.
48. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A et al (2008) 11C-choline positron emission tomography/computerized tomography for preoperative lymph node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54: 392-398.
49. Beheshti M, Imamovic L, Broiger G, Vali R, Waldenberger P, Stolber F et al (2010) 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254: 925-933.
50. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A et al (2010) (11C)choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 184: 938-943.